Why making the argument isn’t enough
Most CMOs in PE-backed healthcare organizations already know that marketing should be framed as a financial function. They have made the argument. They have presented the framework. They have explained attribution, healthcare marketing EBITDA contribution, and CAC trends in board meetings. And in many cases, the operating partners nodded, the presentation ended, and the next budget cycle still treated marketing as overhead.
The problem is not the argument. The problem is that the argument arrived without the evidence base required to make it stick. Operating partners are trained to evaluate capital deployment based on demonstrated returns, not projected ones. A healthcare CMO who argues that marketing is a margin driver without historical data showing that the investment has produced measurable financial outcomes is asking sponsors to extend a form of credit they don’t extend to any other function. The repositioning is not a persuasion problem. It is an evidence problem. And the evidence has to be built before the argument is made.
The sequencing problem: Most healthcare CMOs try to win the argument before building the evidence
The most common repositioning mistake is attempting the narrative change before the measurement infrastructure exists to support it. A CMO who presents a compelling cost-center-to-margin-driver argument in Q1 without attribution data, without location-level healthcare marketing EBITDA contribution reporting, and without a trend line showing CAC improvement has made a promise. By Q3, if the data still doesn’t exist, the promise has become a liability.
The correct sequence is the opposite: build the measurement infrastructure first, accumulate the data for two to three quarters, then present the argument with evidence already in hand. This means that the repositioning conversation the CMO is having with operating partners in year two is substantively different from the one they’re having in year one. In year one, the argument is “trust us, marketing is a financial function.” In year two, with a documented trend line showing CAC declining quarter over quarter and same-site revenue contribution growing, the argument is “here is what our capital deployment has produced.” Those are not the same conversation.
What the evidence base needs to show
Three evidence streams, sustained over at least two to three quarters, are what move the repositioning from argument to fact. The first is a direct correlation between marketing investment and location-level revenue outcomes, not portfolio-level averages, but specific locations where increased marketing spend produced documentable revenue improvement in the subsequent quarter. A one-location example is an anecdote. The same pattern across eight or ten locations is a model.
The second is De Novo ramp performance data comparing locations that received the full pre-opening marketing program against those that received a compressed or partial one. If the full-program locations are consistently ramping six to eight months faster than the partial-program locations, that gap has a calculable IRR value that the operating partner can put in a model. The third is a CAC trend line showing quarter-over-quarter improvement. Not a single good quarter, a trend. A trend makes performance predictable, and predictability is what sponsors are paying a multiple for. One quarter of efficient acquisition is noise. Six quarters of declining CAC is a system.
What changes in the board meeting when the evidence exists
The experience of presenting marketing as a financial function with a two-year evidence base is qualitatively different from presenting it as a strategic intention. Operating partners who previously engaged with the marketing section of a board presentation as a necessary formality, nodding through the campaign updates to get back to the financial discussion, engage differently when the marketing section leads with healthcare marketing EBITDA contribution data, location-level performance attribution, and a documented trend line.
The most visible change is in the questions. A board presentation that leads with campaign performance generates questions about whether the agency is the right one and whether the budget is the right size. A board presentation that leads with “marketing contributed $X in same-site EBITDA last quarter across Y locations, and here is the attribution methodology” generates questions about which markets have the most remaining opportunity and what the IRR impact would be of accelerating the launch program for the next cohort of De Novo openings. Those are capital allocation questions, not marketing evaluation questions. The shift in question type is the clearest indicator that the repositioning has worked.
What repositioning requires internally
Repositioning marketing as a margin driver has internal organizational implications that most CMOs underestimate. The measurement infrastructure that makes the evidence base possible requires cooperation from finance (for production revenue data), operations (for scheduling and patient data), and IT (for the integrations that connect the marketing stack to the practice management system). None of those functions are natural marketing allies in a PE-backed healthcare organization, and none of them will prioritize the attribution build unless the CMO has made an explicit case for why it matters to the business, not to marketing.
The internal case is simpler than the board case: without the data to connect marketing investment to financial outcomes, operating partners will treat marketing as overhead and cut it when pressure mounts. The attribution build protects the marketing budget by making its contribution undeniable. That argument lands differently with a CFO than “we need better analytics,” and the CMOs who have made the internal case on those terms tend to get the integrations prioritized faster than those who framed it as a marketing capability improvement.
“The repositioning from cost center to margin driver is not a narrative exercise. It is a two-year evidence build, and the CMOs who succeed at it start the build before they make the argument.”
How you know it’s worked
The repositioning is complete when three things are true simultaneously. The healthcare marketing budget is defended not by the CMO but by the operating partners, who treat it as capital with a documented return rather than overhead with a hoped-for benefit. The attribution data is trusted by finance as a legitimate reporting input, not viewed skeptically as a marketing self-assessment. And the conversation about growing the healthcare marketing budget is framed around expected IRR rather than around creative ambition or brand goals.
Reaching that point typically takes 18 to 24 months from the start of a deliberate build, six months to get the measurement infrastructure in place, two to three quarters to accumulate meaningful trend data, and one to two board cycles to present it in a format that changes the dynamic. It is not a quick win. It is a structural change to how marketing is understood inside the organization, and it is the change that determines whether the healthcare CMO has a durable seat at the leadership table or a perpetually defended one.
Agency Creative helps multi-site healthcare CMOs build the measurement infrastructure and evidence base that makes the cost-center-to-margin-driver shift real, starting with the attribution build and the reporting layer that produces the data operating partners will trust. Let’s talk about where you are in that build.
Learn how Agency Creative can help boost your brand by calling us at 972.488.1660 or by contacting us online.
See More Work
